Silencing of the BRCA1 gene by promoter hyper-methylation has also been detected in primary breast and ovarian carcinomas, especially during loss of heterozygosity and in specific histopathologic subgroups [10]. This evidence concerns the gene BRCA1 and ovarian carcinoma.